Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease

被引:245
|
作者
Fedorow, H
Tribl, F
Halliday, G
Gerlach, A
Riederer, P
Double, KL
机构
[1] Prince Wales Med Res Inst, Randwick, NSW 2031, Australia
[2] Univ Wurzburg, Clin & Polyclin Psychiat & Psychotherapy, Wurzburg, Germany
[3] Univ Wurzburg, Dept Child & Adolescent Psychiat & Psychotherapy, Wurzburg, Germany
基金
英国医学研究理事会;
关键词
neuromelanin; dopamine; Parkinson's disease; melanin; human brain;
D O I
10.1016/j.pneurobio.2005.02.001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neuromelanin (NM) is a dark polymer pigment produced in specific populations of catecholaminergic neurons in the brain. It appears in greatest quantities in the human brain, in lesser amounts in some other non-human primates, but is absent from the brain in many lower species. Interest in this pigment has seen a resurgence in recent years because of a hypothesised link between neuromelanin and the especial vulnerability of neuromelanin-containing neurons to cell death in Parkinson's disease (PD). Little is known regarding the biology of neuromelanin. As neuromelanin appears to have characteristics in common with the better studied peripheral melanin pigments this review compares what is known about neuromelanin with melanins found in other body tissues. Unlike peripheral melanins, which are produced in specialised cells called melanocytes and may be transferred to other cell types, neuromelanin granules are believed to be stored in the cell in which they are produced. Neuromelanin granules display a unique, more heterogeneous appearance compared with peripheral melanins. Unlike melanin, neuromelanin is traditionally thought to result from a non-enzymatic synthesis pathway with no known pathway for neuromelanin catabolism. More recent data, however, is indicative of some regulation of neuromelanin synthesis and turnover. By analogy with peripheral melanins, neuromelanin may function in vivo to attenuate the effects of damaging stimuli. Among several possible mechanisms suggested, the ability of neuromelanin to interact with transition metals, especially iron, and to mediate intracellular oxidative mechanisms has received particular attention. Recent data from neuromelanin in the Parkinson's disease brain suggests that this proposed function may be compromised, thus rendering pigmented neurons vulnerable to oxidative damage in this disorder. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:109 / 124
页数:16
相关论文
共 50 条
  • [41] Dopamine modulates the response of the human amygdala: A study in Parkinson's disease
    Tessitore, A
    Hariri, AR
    Fera, F
    Smith, WG
    Chase, TN
    Hyde, TM
    Weinberger, DR
    Mattay, VS
    JOURNAL OF NEUROSCIENCE, 2002, 22 (20) : 9099 - 9103
  • [42] In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease
    Gonzalez-Sepulveda, Marta
    Compte, Joan
    Cuadros, Thais
    Nicolau, Alba
    Guillard-Sirieix, Camille
    Penuelas, Nuria
    Lorente-Picon, Marina
    Parent, Annabelle
    Romero-Gimenez, Jordi
    Cladera-Sastre, Joana M.
    Laguna, Ariadna
    Vila, Miquel
    BRAIN, 2023, 146 (03) : 1040 - 1052
  • [43] The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease
    Mackie, Phillip
    Lebowitz, Joe
    Saadatpour, Leila
    Nickoloff, Emily
    Gaskill, Peter
    Khoshbouei, Habibeh
    BRAIN BEHAVIOR AND IMMUNITY, 2018, 70 : 21 - 35
  • [44] Intracerebroventricular dopamine for Parkinson's disease
    Devos, David
    Devedjian, Jean-Christophe
    Moreau, Caroline
    ONCOTARGET, 2017, 8 (28) : 45034 - 45035
  • [45] Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
    Vila, Miquel
    MOVEMENT DISORDERS, 2019, 34 (10) : 1440 - 1451
  • [46] Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease
    B. Caronti
    G. Antonini
    C. Calderaro
    S. Ruggieri
    G. Palladini
    F. E. Pontieri
    C. Colosimo
    Journal of Neural Transmission, 2001, 108 : 803 - 807
  • [47] Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease
    Taniguchi, Daisuke
    Hatano, Taku
    Kamagata, Koji
    Okuzumi, Ayami
    Oji, Yutaka
    Mori, Akio
    Hori, Masaaki
    Aoki, Shigeki
    Hattori, Nobutaka
    MOVEMENT DISORDERS, 2018, 33 (09) : 1488 - 1492
  • [48] Spatial RNA Sequencing Identifies Robust Markers of Vulnerable and Resistant Human Midbrain Dopamine Neurons and Their Expression in Parkinson's Disease
    Aguila, Julio
    Cheng, Shangli
    Kee, Nigel
    Cao, Ming
    Wang, Menghan
    Deng, Qiaolin
    Hedlund, Eva
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2021, 14
  • [49] Dopamine receptor mapping with PET imaging in Parkinson's disease
    Niccolini, Flavia
    Su, Paul
    Politis, Marios
    JOURNAL OF NEUROLOGY, 2014, 261 (12) : 2251 - 2263
  • [50] Neuromelanin Magnetic Resonance Imaging in Parkinson's Disease and Multiple System Atrophy
    Matsuura, Keita
    Maeda, Masayuki
    Yata, Kenichiro
    Ichiba, Yoshito
    Yamaguchi, Tomoya
    Kanamaru, Kenji
    Tomimoto, Hidekazu
    EUROPEAN NEUROLOGY, 2013, 70 (1-2) : 70 - 77